Survanta Market Report 2026

Survanta Market Overview

• The Survanta market growth in the historic period has been driven by rising premature birth rates, increased awareness of neonatal respiratory distress syndrome • Market expansion is supported by increasing focus on advanced neonatal care technologies, expansion of neonatal healthcare access in emerging markets • Growth Driver: Impact Of Increasing Prevalence Of Premature Births On The Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Survanta Market?

Survanta is a surfactant medication used to treat or prevent respiratory distress syndrome (RDS) in premature infants. It works by replacing the natural surfactant in the lungs, which helps reduce surface tension in the alveoli, improving breathing and oxygen exchange. The medication is administered directly into the lungs to enhance their function and support respiratory stability. The main indications of survanta are respiratory distress syndrome (RDS), meconium aspiration syndrome (MAS), bronchopulmonary dysplasia (BPD), acute respiratory failure, and other indications. Respiratory Distress Syndrome (RDS) is a condition commonly seen in premature infants where the lungs lack sufficient surfactant, leading to difficulty breathing and inadequate oxygen exchange. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and public health clinics, and it is used for pediatric patients.

What Is The Survanta Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on advanced neonatal care technologies, expansion of neonatal healthcare access in emerging markets, ongoing clinical research in lung maturation therapies, rising demand for early intervention treatments, improved neonatal drug delivery methods. Major trends in the forecast period include increasing use of surfactant replacement therapies, growing focus on neonatal respiratory care, expansion of nicu infrastructure globally, improved administration techniques for premature infants, enhanced clinical protocol standardization.

Global Survanta Market Segmentation

1) By Indication: Respiratory Distress Syndrome (RDS), Meconium Aspiration Syndrome (MAS), Bronchopulmonary Dysplasia (BPD), Acute Respiratory Failure, Other Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Public Health Clinics 3) By End-User: Pediatric

What Are The Drivers Of The Survanta Market?

The increasing prevalence of premature births is significantly driving the growth of the survanta market in the future. Premature births occur when a baby is born before 37 weeks of pregnancy, leading to underdeveloped organs and increased health risks. The increasing prevalence of premature births can be attributed to factors such as advanced maternal age, lifestyle choices, increased prevalence of chronic conditions, and advancements in fertility treatments. Survanta is used in premature births to treat respiratory distress syndrome (RDS), a condition common in premature infants due to insufficient surfactant production in their lungs, helping improve lung function and reduce the risk of complications. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, the preterm birth rate was 10.41% in 2024. Therefore, increasing the prevalence of premature births is driving the growth of the survanta industry. Increasing investments in maternal and child health are expected to propel the growth of the survanta market going forward. Maternal and child health refers to the well-being of women during pregnancy, childbirth, and the postpartum period, as well as the health and development of children, particularly in the early years of life. Increasing investments in maternal and child health are driven by the need to reduce maternal and infant mortality, improve healthcare access, and promote long-term social and economic development. Investment in maternal and child health ensures access to life-saving treatments such as survanta, reducing neonatal mortality from respiratory distress syndrome. For instance, in September 2024, the American Hospital Association, a US-based professional organization, reported that the Department of Health and Human Services allocated over $558 million (USD 0.558) to maternal health initiatives, including $440 million (USD 0.44) for home visiting services and $118.5 million (USD 0.1185) for CDC programs. Thus, the increasing investments in maternal and child health are driving the growth of the survanta industry. The growing number of infant hospital admissions is set to propel the growth of the Survanta market moving forward. The growing number of infants' hospital admissions can be attributed to factors such as increasing rates of premature births, higher incidences of neonatal and respiratory conditions, improved survival rates leading to more complex care needs, and greater access to healthcare facilities. Survanta is utilized during infant hospitalizations to treat respiratory distress syndrome (RDS) in premature newborns, enhancing lung function and minimizing complications. For instance, in May 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, hospital admissions of infants under 14 days increased from 81.6 per 1,000 population in the fiscal year 2022 to 84.8 per 1,000 population in the fiscal year 2023. Therefore, the growing number of infant hospital admissions will drive the growth of the survanta industry.

Key Players In The Global Survanta Market

Major companies operating in the survanta market are AbbVie Ltd.

Regional Insights

North America was the largest region in the survanta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Survanta Market?

The survanta market consists of sales of surfactant delivery devices, neonatal respiratory care kits, syringes, and injection systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Survanta Market Report 2026?

The survanta market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the survanta industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.